Europe, Switzerland, and South Korea now face 15% tariffs on patented pharmaceuticals under President Trump's April 2 Section 232 proclamation, while the UK faces rates between 0-10% and generics and biosimilars remain exempt at 0%. The investigation cites that 53% of patented pharmaceuticals and 85% of active pharmaceutical ingredients are manufactured offshore as the national security rationale.

Country-Specific Rates Under Section 232:
• European Union: 15%
• Switzerland: 15%
• South Korea: 15%
• United Kingdom: 0-10%
• Generics/Biosimilars (all origins): 0%

Seventeen major pharmaceutical companies that signed agreements with the Department of Health and Human Services will pay either 0% or 20% tariffs depending on their deal terms. Companies committing to most-favoured-nation pricing, US investments, and onshoring manufacturing receive exemptions valid until January 20, 2029. Compliance teams should flag these HHS agreements as a critical data point for duty calculation on shipments from covered entities.

Six niche therapy categories receive blanket exemptions regardless of origin: orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, and antibody-drug conjugates. These classifications will require precise HTS mapping to ensure automated systems correctly apply the 0% rate.

Country of Origin Complexity: US Customs may determine India as the country of origin for APIs and intermediates manufactured by Indian CDMOs even when products are not shipped directly to the US. This ruling affects transfer pricing structures and may trigger higher tariff rates on finished products incorporating Indian-origin components.

According to Jefferies analyst Alok Dalal, most large pharmaceutical firms have signed HHS agreements qualifying for zero tariffs, while biotech companies typically maintain single-supplier relationships per product. Nomura analyst Sion Mukherjee noted that adding new suppliers requires 12-24 months, and Indian API manufacturing costs run 30-40% below US and European levels—suggesting continued India-based sourcing despite tariff exposure on certain classifications.

For trade compliance engineering teams, this proclamation introduces multi-variable rate determination: country of origin, HHS agreement status, product classification (patented vs. generic vs. biosimilar), and niche therapy categorization all affect the applicable duty rate. Systems pulling HTS data must now incorporate these Section 232 pharmaceutical-specific overlays to return accurate rates.

TradeFacts.io tracks these changes nightly. Start a free 30-day trial.